## Rule 2.7, 3.10.3, 3.10.4, 3.10.5 Appendix 3B

## New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Nearmap Ltd

ABN

37 083 702 907

We (the entity) give ASX the following information.

## Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of +securities issued or to be issued

**Director Options** 

- 2 Number of \*securities issued or to be issued (if known) or maximum number which may be issued
- Principal of the terms 3 +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

812,101 Director Options

Director Options exercisable at \$2.478 each on or before 14 November 2023, vesting on 14 November 2022 subject to performance vesting conditions detailed in the Company's notice of meeting dated 15 October 2019.

<sup>+</sup> See chapter 19 for defined terms.

4	<ul> <li>Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?</li> <li>If the additional *securities do not rank equally, please state: <ul> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul> </li> </ul>	No. Options over unissued shares may only be exercised in accordance with their terms and conditions. On conversion of the Options to shares, the shares will rank equally with existing shares.
5	Issue price or consideration	Nil
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Director Options issued to Managing Director/ CEO as a long term incentive, as approved by shareholders on 14 November 2019
6a	Is the entity an <sup>+</sup> eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h <i>in relation to the <sup>+</sup>securities the</i> <i>subject of this Appendix 3B</i> , and comply with section 6i	No
6b	The date the security holder resolution under rule 7.1A was passed	N/A
6с	Number of <sup>+</sup> securities issued without security holder approval under rule 7.1	N/A
6d	Number of *securities issued with security holder approval under rule 7.1A	N/A

<sup>+</sup> See chapter 19 for defined terms.

- 6e Number of \*securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)
- 6f Number of +securities issued under an exception in rule 7.2
- 6g If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.
- 6h If \*securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements
- 6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements
- 7 <sup>+</sup>Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

8 Number and <sup>+</sup>class of all <sup>+</sup>securities quoted on ASX (*including* the <sup>+</sup>securities in section 2 if applicable)

Number	+Class
450,949,366 1. 8,665,042 shares subject to holding lock pursuant to loan provisions of the Company's ESOP	Ordinary fully paid shares

N/A

N/A

N/A

N/A

15 November 2019

+ See chapter 19 for defined terms.

	Number	+Class
9 Number and <sup>+</sup> class of all <sup>+</sup> securities not quoted on ASX ( <i>including</i> the <sup>+</sup> securities in section 2 if applicable)	14,680,535	ESOP Options to acquire fully paid ordinary shares. The options expire on various dates between 30/11/2019 and 2/01/2023 and are exercisable at a range of prices between \$0.39 and \$2.97 each.
	1,101,456	LTIP Options over Ordinary Shares with an exercise price of \$2.575 and expiry date of 01/10/2023.
	1,095,072	RSUs, being an entitlement to be issued Ordinary Shares.

10	Dividend policy (in the case of a	N/A
	trust, distribution policy) on the	
	increased capital (interests)	

# Part 2 - Pro rata issue

11	Is security holder approval N required?	/A
12	Is the issue renounceable or non- N renounceable?	/A
13	Ratio in which the <sup>+</sup> securities N will be offered	/A
14	<sup>+</sup> Class of <sup>+</sup> securities to which the N offer relates	/A
15	<sup>+</sup> Record date to determine N entitlements	/A
16	Will holdings on different N registers (or subregisters) be aggregated for calculating entitlements?	/A

<sup>+</sup> See chapter 19 for defined terms.

- Policy for deciding entitlements 17 Ν in relation to fractions
- Names of countries in which the 18 entity has security holders who will not be sent new offer documents

Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.

Closing date for receipt 19 of acceptances or renunciations

Names of any underwriters 20

- Amount of any underwriting fee 21 or commission
- Names of any brokers to the N/A 22 issue
- Fee or commission payable to 23 the broker to the issue
- Amount of any handling fee 24 payable to brokers who lodge acceptances or renunciations on behalf of security holders
- If the issue is contingent on 25 security holders' approval, the date of the meeting
- Date entitlement and acceptance 26 form and offer documents will be sent to persons entitled
- If the entity has issued options, 27 and the terms entitle option holders participate to on exercise, the date on which notices will be sent to option holders
- Date rights trading will begin (if | N/A 28 applicable)

I/A		

N/A

N/A N/A

N/A

N/A

N/A

N/A

N/A

N/A

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3B New issue announcement

29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	<sup>+</sup> Issue date	N/A

### Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- 34 Type of \*securities (*tick one*)
- (a) <sup>+</sup>Securities described in Part 1
  - All other +securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

#### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35

(b)

If the \*securities are \*equity securities, the names of the 20 largest holders of the additional \*securities, and the number and percentage of additional \*securities held by those holders

<sup>+</sup> See chapter 19 for defined terms.

36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
37	A copy of any trust deed for the additional *securities
Entiti	es that have ticked box 34(b)
38	Number of <sup>+</sup> securities for which <sup>+</sup> quotation is sought
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought
40	Do the <sup>+</sup> securities rank equally in all respects from the <sup>+</sup> issue date with an existing <sup>+</sup> class of quoted <sup>+</sup> securities?
	<ul> <li>If the additional <sup>+</sup>securities do not rank equally, please state:</li> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of
	another <sup>+</sup> security, clearly identify that other <sup>+</sup> security)

<sup>+</sup> See chapter 19 for defined terms.

42 Number and <sup>+</sup>class of all <sup>+</sup>securities quoted on ASX (*including* the <sup>+</sup>securities in clause 38)

	Number	+Class
ıll		
Х		
se		

#### Quotation agreement

- <sup>1</sup> <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

<sup>+</sup> See chapter 19 for defined terms.

Vamon ( soto)

15 November 2019

SHANNON COATES

Print name:

ne: .....

<sup>+</sup> See chapter 19 for defined terms.

Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

## Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
<i>Insert</i> number of fully paid <sup>+</sup> ordinary securities on issue 12 months before the <sup>+</sup> issue date or date of agreement to issue	N/A	
Add the following:		
<ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period under an exception in rule 7.2</li> </ul>		
<ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period with shareholder approval</li> </ul>		
<ul> <li>Number of partly paid <sup>+</sup>ordinary securities that became fully paid in that 12 month period</li> </ul>		
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
<b>Subtract</b> the number of fully paid <sup>+</sup> ordinary securities cancelled during that 12 month period		
"A"		

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<i>Multiply</i> "A" by 0.15		
Step 3: Calculate "C", the amount of that has already been used	of placement capacity under rule 7.1	
<i>Insert</i> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:		
Under an exception in rule 7.2		
Under rule 7.1A		
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>		
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"		
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	3"] to calculate remaining	
"A" x 0.15		
Note: number must be same as shown in Step 2		
Subtract "C"		
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"		
	[Note: this is the remaining placement capacity under rule 7.1]	

<sup>+</sup> See chapter 19 for defined terms.

## Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"		
<i>Note: number must be same as shown in Step 1 of Part 1</i>		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
<i>Multiply</i> "A" by 0.10		
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<i>Insert</i> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period under rule 7.1A		
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	
Note: number must be same as shown in Step 2	
Subtract "E"	
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.10] – "E"	
	Note: this is the remaining placement capacity under rule 7.1A

<sup>+</sup> See chapter 19 for defined terms.